May 6 |
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
|
Apr 16 |
With 54% institutional ownership, Apogee Therapeutics, Inc. (NASDAQ:APGE) is a favorite amongst the big guns
|
Apr 3 |
Paragon’s hub-and-spoke biotech model yields another reverse merger
|
Mar 28 |
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
|
Mar 25 |
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
|
Mar 12 |
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
|
Mar 8 |
Apogee Therapeutics stock slides on pricing upsized stock offering to raise $420 million
|
Mar 7 |
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
|
Mar 6 |
Apogee Therapeutics: Success In Phase 1 Bodes Well For Continued APG777 Advancement
|
Mar 6 |
Apogee Highlights Corporate reports FY results
|